Jonathan Roses counsels an array of clients, including life sciences companies focused on the areas of small molecule pharmaceuticals, pharmaceutical formulations, medical devices and surgical methods. Jonathan is highly skilled in conducting and managing domestic and foreign patent prosecution and pre-litigation investigations, including worldwide freedom to operate, patentability and exclusivity analyses. He is also experienced in representing clients in federal district court litigation and in post-grant proceedings before the United States Patent and Trademark Office and foreign counterparts. Jonathan has also provided regulatory advice and representation to clients relating to patent term extension and Orange Book listings under the Hatch-Waxman Act. He has a proven track record of building client relationships, teaching and mentoring junior attorneys, and providing top-notch service and results.

Jonathan is active in the Boston Patent Law Association (BPLA), having served as co-chair of the Patent Office Practice Committee since 2017, and having authored or co-authored several response to Requests for Comments from the USPTO on behalf of BPLA on issues related to subject matter eligibility, motions to amend and claim construction standards in post-grant proceedings, proposed changes to regulations promulgated under the Bayh-Dole Act, patenting artificial intelligence inventions, and expanding diversity and inclusion in the American innovation system.

Prior to joining Wolf Greenfield, Jonathan served as Counsel at Wilmer Hale, where he prosecuted and managed prosecution of patent applications worldwide for domestic and foreign life sciences, universities and consumer clients in the chemical, pharmaceutical, biotechnology and materials science arts. He represented innovator pharmaceutical companies in ANDA (Hatch-Waxman) and 505(b)(2) patent infringement litigations involving Paragraph III and IV challenges of Orange Book listed patents covering several blockbuster drugs.

Before beginning his legal career, Jonathan was a medicinal chemist at Ariad Pharmaceuticals and Millennium Pharmaceuticals.

Client testimonial:
"The IP Jonathan has helped us generate will be transformative."

Represented U.S. subsidiary of 140-year old global pharmaceutical company based in Japan in parallel Inter Partes Review (“IPR”) and federal district court Hatch-Waxman proceedings related to its antihyperglycemic drug used in the management of type 2 diabetes. Won in a Final Written Decision on all claims of one patent after taking deposition of defendants’ sole expert witness and presenting oral argument before the United States Patent and Trademark Office’s Patent Trial and Appeals Board. Achieved Denial of Institution for two Petitions filed on another patent related to the same drug.
Represented global pharmaceutical company in Hatch-Waxman patent litigation related to its subsidiary’s blockbuster oncology drug. Achieved a significant victory at the Court of Appeals for the Federal Circuit when the appeals court reversed a district court finding of patent invalidity based on obviousness and remanded the case with instructions to enter judgment in favor of the client. Further representation for second wave of defendants in the United States and foreign counterpart litigation and post-grant proceedings.
Managed a global patent portfolio and provided strategic advice on behalf of a United States-based antibiotics company. The portfolio included well over 600 matters, including nearly 200 pending applications and over 300 granted patents, and included three approved products and one clinical stage candidate.
Provided regulatory advice related to and performed regulatory submissions to the Food and Drug Administration, including providing advice on and drafting forms for listing of patent information in the Orange Book and providing advice on, drafting, and filing Patent Term Extension applications related to both drug products and medical devices.
Advised non-profit foundation that manages a historic house museum in Washington, D.C. on strategic trademark prosecution, brand building and protection, and collaboration agreements with brewers and food scientists to produce historic recreations of pre- and post-prohibition era beer offerings.
Performed intellectual property due diligence investigations related to investments in and acquisitions by a range of domestic and foreign companies in the areas of small molecule pharmaceuticals, and software related to implementation of medical technology and healthcare administration. Analyses included freedom-to-operate, patentability, market exclusivity, and confirmation of status (such as pendency, enforceability, and ownership).

American Chemical Society (1999-present)
American Institute of Chemists (1999-present)
American Bar Association, Intellectual Property Section (2007-present)
Boston Bar Association (2007-present)
Boston Patent Law Association (2007-present), Patent Office Practice Committee Co-Chair (2017-present)

Named to the Massachusetts Super Lawyers list (2021)
Named to the list of Massachusetts Rising Stars by Super Lawyers (2015-2020)
Harvard CopyrightX (2015)
Boston College Law School Environmental Law Society Regulatory Skills Series (2007)

IP Alerts

June 11, 2020

IP Deadline Extensions Across the Globe Due to COVID-19

Articles

Blogs

March 16, 2021

2020 Year in Review: Patent Decisions Impacting the Life Sciences

March 16, 2020

Lessons on Inherency Challenges After Hospira v. Fresenius Kabi USA

February 19, 2020

The Federal Circuit Giveth, And The Federal Circuit Taketh Away

Recent News & Events

October 13, 2021

Wolf Greenfield Attorneys Named to 2021 Massachusetts Super Lawyers, Rising Stars Lists

September 22, 2021 1:00 PM - 2:00 PM ET

Tech Transfer Central: Critical Issues in Due Diligence and Freedom to Operate Analysis for University IP

March 25, 2021 2:45 PM - 6:15 PM ET

ACI’s FDA Boot Camp: Hatch-Waxman and BPCIA in the Trenches: Exclusivity and Bioequivalency Working Group

February 8, 2021

Jonathan Roses Quoted by Bloomberg Law on Why Orange Book Patent Challenges are Down

October 13, 2020

Wolf Greenfield Attorneys Named to 2020 Massachusetts Super Lawyers, Rising Stars Lists

October 7, 2020

Jonathan Roses’ Response to Request For Comments Cited in USPTO’s AI Report

September 24, 2020 2:45 PM - 6:15 PM ET

ACI’s FDA Boot Camp: Hatch-Waxman and BPCIA in the Trenches: Exclusivity and Bioequivalency Working Group

September 17, 2020 12:00 PM - 1:00 PM ET

BPLA: Six Months of Shutdown: What Have I Missed?

March 24, 2020

Jonathan Roses Co-Authors Response on Patenting AI Inventions

Expand All

Before beginning his legal career, Jonathan was a medicinal chemist at Ariad Pharmaceuticals and Millennium Pharmaceuticals.

Client testimonial:
"The IP Jonathan has helped us generate will be transformative."

Represented U.S. subsidiary of 140-year old global pharmaceutical company based in Japan in parallel Inter Partes Review (“IPR”) and federal district court Hatch-Waxman proceedings related to its antihyperglycemic drug used in the management of type 2 diabetes. Won in a Final Written Decision on all claims of one patent after taking deposition of defendants’ sole expert witness and presenting oral argument before the United States Patent and Trademark Office’s Patent Trial and Appeals Board. Achieved Denial of Institution for two Petitions filed on another patent related to the same drug.
Represented global pharmaceutical company in Hatch-Waxman patent litigation related to its subsidiary’s blockbuster oncology drug. Achieved a significant victory at the Court of Appeals for the Federal Circuit when the appeals court reversed a district court finding of patent invalidity based on obviousness and remanded the case with instructions to enter judgment in favor of the client. Further representation for second wave of defendants in the United States and foreign counterpart litigation and post-grant proceedings.
Managed a global patent portfolio and provided strategic advice on behalf of a United States-based antibiotics company. The portfolio included well over 600 matters, including nearly 200 pending applications and over 300 granted patents, and included three approved products and one clinical stage candidate.
Provided regulatory advice related to and performed regulatory submissions to the Food and Drug Administration, including providing advice on and drafting forms for listing of patent information in the Orange Book and providing advice on, drafting, and filing Patent Term Extension applications related to both drug products and medical devices.
Advised non-profit foundation that manages a historic house museum in Washington, D.C. on strategic trademark prosecution, brand building and protection, and collaboration agreements with brewers and food scientists to produce historic recreations of pre- and post-prohibition era beer offerings.
Performed intellectual property due diligence investigations related to investments in and acquisitions by a range of domestic and foreign companies in the areas of small molecule pharmaceuticals, and software related to implementation of medical technology and healthcare administration. Analyses included freedom-to-operate, patentability, market exclusivity, and confirmation of status (such as pendency, enforceability, and ownership).

American Chemical Society (1999-present)
American Institute of Chemists (1999-present)
American Bar Association, Intellectual Property Section (2007-present)
Boston Bar Association (2007-present)
Boston Patent Law Association (2007-present), Patent Office Practice Committee Co-Chair (2017-present)

Named to the Massachusetts Super Lawyers list (2021)
Named to the list of Massachusetts Rising Stars by Super Lawyers (2015-2020)
Harvard CopyrightX (2015)
Boston College Law School Environmental Law Society Regulatory Skills Series (2007)